Company Filing History:
1 out of 676 
1 out of 158 
Years Active: 2006
Title: Valérie Calenda: Innovator in Connective Tissue Research
Introduction
Valérie Calenda is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of biotechnology, particularly in the area of connective tissue growth factors. His work has implications for therapeutic applications in wound healing and tissue repair.
Latest Patents
Valérie Calenda holds a patent for a human CTGF-2 polypeptide and the DNA (RNA) encoding such polypeptide. The invention includes a procedure for producing the polypeptide through recombinant techniques. Additionally, it encompasses antibodies and antagonists/inhibitors against the polypeptide. The patent also outlines methods for using the polypeptide therapeutically to stimulate angiogenesis, enhance the repair of connective and support tissue, promote the attachment and stabilization of tissue implants, and improve wound healing. Furthermore, diagnostic assays for identifying mutations in the nucleic acid sequence encoding the polypeptide and for detecting altered levels of the polypeptide are disclosed.
Career Highlights
Throughout his career, Valérie Calenda has worked with prominent companies in the biotechnology sector, including Human Genome Sciences, Inc. and Transgene S.A. His experience in these organizations has contributed to his expertise in the development of innovative therapeutic solutions.
Collaborations
Valérie has collaborated with notable colleagues such as Haodong Li and Mark D Adams. These partnerships have likely enriched his research and development efforts in the field of connective tissue growth factors.
Conclusion
Valérie Calenda's contributions to biotechnology, particularly through his patent on CTGF-2, highlight his role as an innovator in the field. His work not only advances scientific understanding but also holds promise for therapeutic applications in medicine.